Zilretta: Clinical Trials

10 trials of Zilretta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 terminated, 1 unknown. 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 210Completed 5, Terminated 4, Unknown 1

Follow Zilretta: new trials by email Literature Review of Zilretta trials Research Report on Zilretta

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip
Zilretta, Triamcinolone Acetonide - Osteoarthritis of Hip
Phase 2TerminatedPacira Pharmaceuticals, Inc12025-07-252025-12-22
Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis
Resiniferatoxin, Zilretta, Placebo - Osteoarthritis, Knee, Knee Osteoarthritis
Phase 2UnknownSorrento Therapeutics, Inc.1242021-11-152023-01-17
Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury
Zilretta, Placebo - Tibial Meniscus Injuries, Tibial Meniscus Tears
Phase 2TerminatedAustin V Stone12020-08-212023-07-27
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis
FX006, Normal Saline - Osteoarthritis of the Shoulder, Adhesive Capsulitis
Phase 2TerminatedPacira Pharmaceuticals, Inc192019-11-072024-01-24
Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
FX006 32 mg, TAcs 40 mg - Osteoarthritis of the Shoulder, Osteoarthritis of the Hip
Phase 2CompletedPacira Pharmaceuticals, Inc552017-12-182024-01-24
Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
FX006 32 mg, TAcs 40 mg - Bilateral Knee Osteoarthritis
Phase 2CompletedPacira Pharmaceuticals, Inc242017-12-062024-01-24
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
FX006 32 mg, TCA IR 40 mg - Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Phase 2CompletedPacira Pharmaceuticals, Inc332016-04-012024-01-24
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
FX006 32 mg, TCA IR 40 - Osteoarthritis of the Knee
Phase 2CompletedPacira Pharmaceuticals, Inc812015-11-012024-01-24
Proof of Concept Study Comparing FX006 to KenalogĀ®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
FX006 32 mg, TCA IR 40 mg - Post-traumatic Osteoarthritis of the Knee
Phase 2TerminatedPacira Pharmaceuticals, Inc62015-02-012024-01-24
Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee
FX006 32 mg, Placebo, FX006 16 mg - Osteoarthritis of the Knee
Phase 2CompletedPacira Pharmaceuticals, Inc3102014-04-012024-01-24

Conditions studied

Osteoarthritis (8)  ·  Pain (7)  ·  Osteoarthritis, Knee (4)  ·  Osteoarthritis, Hip (2)  ·  Anterior Cruciate Ligament Injuries (1)  ·  Bursitis (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Tibial Meniscus Injuries (1)

Sponsors

Pacira Pharmaceuticals, Inc (8)  ·  Austin V Stone (1)  ·  Sorrento Therapeutics, Inc. (1)

Countries

United States (10)  ·  Canada (1)

Top investigators

Neil Bodick, MD (4)  ·  Scott Kelley, MD (3)  ·  Austin Stone, MD, PhD (1)  ·  Martin Ferrillo (1)  ·  Mike Royal, MD (1)  ·  Nino Joy (1)

Results publications

PMID 29088579, PMID 30203101, PMID 31662801, PMID 34350546, PMID 35258839